Anemia — Causes of Anemia Among Women of Reproductive Age
Citation(s)
Cintron-Garcia J, Guddati AK Effect of immigration on mortality trends in sickle cell patients. Am J Blood Res. 2020 Oct 15;10(5):172-178. eCollection 2020.
Gebreegziabher T, Stoecker BJ Iron deficiency was not the major cause of anemia in rural women of reproductive age in Sidama zone, southern Ethiopia: A cross-sectional study. PLoS One. 2017 Sep 12;12(9):e0184742. doi: 10.1371/journal.pone.0184742. eCollection 2017. Erratum In: PLoS One. 2017 Dec 7;12 (12 ):e0189553.
Khambalia AZ, Aimone AM, Zlotkin SH Burden of anemia among indigenous populations. Nutr Rev. 2011 Dec;69(12):693-719. doi: 10.1111/j.1753-4887.2011.00437.x.
Kibret KT, Chojenta C, D'Arcy E, Loxton D Spatial distribution and determinant factors of anaemia among women of reproductive age in Ethiopia: a multilevel and spatial analysis. BMJ Open. 2019 Apr 4;9(4):e027276. doi: 10.1136/bmjopen-2018-027276.
Kohne E Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Dtsch Arztebl Int. 2011 Aug;108(31-32):532-40. doi: 10.3238/arztebl.2011.0532. Epub 2011 Aug 8.
Liyew AM, Teshale AB Individual and community level factors associated with anemia among lactating mothers in Ethiopia using data from Ethiopian demographic and health survey, 2016; a multilevel analysis. BMC Public Health. 2020 May 24;20(1):775. doi: 10.1186/s12889-020-08934-9.
Teshale AB, Tesema GA, Worku MG, Yeshaw Y, Tessema ZT Anemia and its associated factors among women of reproductive age in eastern Africa: A multilevel mixed-effects generalized linear model. PLoS One. 2020 Sep 11;15(9):e0238957. doi: 10.1371/journal.pone.0238957. eCollection 2020.
Etiology and Contributing Factors of Anemia Among Women of Reproductive Age at Kebribeyah District in the Somali Regional State, Ethiopia
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
